The Dog Aging Project is pleased to announce that the first enrolled dogs, Zoe and Jack, have now completed their participation in the three-year clinical trial, the Test of Rapamycin in Aging Dogs (TRIAD). This is one cohort of the Dog Aging Project and the third clinical trial investigating whether rapamycin can improve aging-related health in older dogs. Initial studies show evidence that small doses of the drug rapamycin help to mitigate or delay the diseases of aging. The plan is to enroll 580 dogs, and they are actively recruiting more participants.
To be considered for TRIAD, a dog needs to be at least 7 years old, between 44 and 120 pounds, spayed or neutered, and in good general health. Participants must bring their dog to a clinical trial site every six months for three years. Sites are located throughout the U.S., including in Wheat Ridge and Fort Collins, CO. Veterinarians are encouraged to share information about this study with their clients, and resources are available online to help do that.
The Dog Aging Project is a community science initiative led by Texas A&M University, the University of Washington, and Tufts University, along with other collaborating institutions. Funding comes from grants, including a 2024 $7 million National Institutes of Health (NIH) award, along with philanthropic donations and support from the Dog Aging Institute.
To learn more, visit the website.
